Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD1 in Metastatic Non-Small Cell Lung Cancer

• Published in: Cancer immunology research 2023-04, Vol.11 (4), p.486-500
• Main Authors: He, Kewen, Barsoumian, Hampartsoum B., Puebla-Osorio, Nahum, Hu, Yun, Sezen, Duygu, Wasley, Mark D., Bertolet, Genevieve, Zhang, Jie, Leuschner, Carola, Yang, Liangpeng, Leyton, Claudia S. Kettlun, Fowlkes, Natalie Wall, Green, Morgan Maureen, Hettrick, Lisa, Chen, Dawei, Masrorpour, Fatemeh, Gu, Meidi, Maazi, Hadi, Revenko, Alexey S., Cortez, Maria Angelica, Welsh, James W.
• Format: Article
• Language: English
• ISSN: 2326-6066; 2326-6074
• DOI: 10.1158/2326-6066.CIR-22-0547

Diverse factors contribute to the limited clinical response to radiotherapy (RT) and immunotherapy in metastatic non-small cell lung cancer (NSCLC), among which is the ability of these tumors to recruit a retinue of suppressive immune cells – such as M2 tumor-associated macrophages (TAMs) – thereby establishing an immunosuppressive-tumor microenvironment that contributes to tumor progression and radio-resistance. M2 TAMs are activated by the signal transducer and activator of transcription 6 (STAT6) signaling pathway. Therefore, we targeted STAT6 using an antisense oligonucleotide (ASO) along with hypofractionated RT (hRT) (3 fractions of 12 Gy each) to primary tumors in three bilateral murine NSCLC models (Lewis lung carcinoma, 344SQ-parental, and anti-PD1-resistant 344SQ lung adenocarcinomas). We found that STAT6 ASO plus hRT slowed growth of both primary and abscopal tumors, decreased lung metastases, and extended survival. Interrogating the mechanism of action showed reduced M2 macrophage tumor infiltration, enhanced T H 1 polarization, improved T cell and macrophage function, and decreased TGFβ levels. The addition of anti-PD-1 further enhanced systemic antitumor responses. These results provide a pre-clinical rationale for the pursuit of an alternative therapeutic approach for patients with immune-resistant NSCLC.